New Biannual HIV Injection Reduces Infection Risk by 96%

Gilead Sciences' lenacapavir shows superior efficacy in Phase 3 trials, offering a promising advancement in HIV prevention.

Gilead Sciences announced lenacapavir's success in reducing HIV infection risk by 96% in two Phase 3 clinical trials.
The trials included diverse populations from multiple countries, with impressive results across all groups.
Lenacapavir demonstrated significantly higher efficacy compared to the once-daily Truvada, with only two infections in the lenacapavir group versus nine in the Truvada group.
The drug's twice-yearly injection format addresses adherence challenges associated with daily oral PrEP medications.
Gilead plans to seek regulatory approval globally by the end of the year, aiming to make lenacapavir widely available for HIV prevention.